In 2006, 19% of FLT3POS cases (FLT3–ITD with 12% and FLT3-TKD with 6.7%) were detected in a group of 630 de novo AML pediatric patients, belonging to the Children's Cancer Group. This evidence concerns the gene FLT3 and acute myeloid leukemia.